Inflammatory profiling of Schwann cells manifested as an upregulation of cytokines is present after traumatic or disease injury of the peripheral nerves. Inflammatory activation of Schwann cells via Toll-like receptors (TLRs) can be triggered by exogenous pathological molecules or endogenous ligands produced during Wallerian degeneration. We investigated the early period of inflammatory reactions by following the levels of TLR4, NFκB, IL-1β, pSTAT3, and IL-6 proteins after LPS treatment of RT4 schwannoma cells under in vitro conditions. Significantly increased levels of NFκB, IL-1β, pSTAT3, and IL-6 proteins were found 1 h after LPS action indicating their involvement in the initiation of the inflammatory reaction of schwannoma cells. This initiation was induced without increased TLR4 protein expression, but was accompanied by the appearance of TLR4 in early endosomes. The protein levels decreased within the next 6 h of treatment with a subsequent increase of NFκB, IL-1β, and pSTAT3 after 24 h of LPS treatment. In contrast, continuous decrease of IL-6 over time following LPS treatment was unexpected. Levels of soluble IL-6 protein in the culture medium also decreased with decreasing levels of LPS over 24 h.

Department of Anatomy Division of Neuroanatomy Faculty of Medicine Masaryk University Kamenice 3 625 00 Brno Czech Republic

Faculty of Science RECETOX Research Centre for Toxic Compounds in the Environment Masaryk University Brno Czech Republic

Zobrazit více v PubMed

J Neuroinflammation. 2011 Aug 30;8:110 PubMed

Nat Rev Neurosci. 2007 Mar;8(3):221-32 PubMed

J Biol Chem. 2004 May 7;279(19):19936-47 PubMed

Front Mol Neurosci. 2017 Feb 17;10 :38 PubMed

EMBO J. 2006 Feb 22;25(4):683-92 PubMed

Science. 2007 Jul 6;317(5834):121-4 PubMed

Neurobiol Dis. 2013 Jul;55:95-103 PubMed

Neuromuscul Disord. 1996 Mar;6(2):105-14 PubMed

Cytokine Growth Factor Rev. 2012 Jun;23(3):85-97 PubMed

Biomed Rep. 2015 Mar;3(2):141-146 PubMed

Semin Immunol. 2007 Feb;19(1):24-32 PubMed

Neural Regen Res. 2017 Apr;12 (4):518-524 PubMed

Neuroscience. 2002;113(2):273-87 PubMed

J Exp Med. 2003 Nov 17;198(10):1517-25 PubMed

Brain Behav Immun. 2007 Jul;21(5):522-7 PubMed

EMBO J. 2012 Mar 21;31(6):1350-63 PubMed

Nature. 2013 Sep 12;501(7466):173-5 PubMed

Neuroimmunomodulation. 2010;17(5):314-24 PubMed

J Biol Chem. 2001 Aug 17;276(33):31332-9 PubMed

Prog Neurobiol. 1997 Aug;52(5):379-90 PubMed

Curr Mol Med. 2002 Jun;2(4):381-92 PubMed

Mol Cell Biol. 1990 May;10(5):2327-34 PubMed

Nat Rev Neurosci. 2003 May;4(5):376-85 PubMed

Pharmacol Res. 2017 Jan;115:224-232 PubMed

J Neurochem. 2009 Feb;108(3):776-86 PubMed

Cancer Cell. 2009 Apr 7;15(4):283-93 PubMed

J Neurosci. 2007 Nov 14;27(46):12565-76 PubMed

Semin Immunol. 2014 Feb;26(1):54-74 PubMed

Int Rev Neurobiol. 2013;108:173-206 PubMed

J Neuroinflammation. 2011 Aug 30;8:109 PubMed

Biomed Res Int. 2014;2014:691041 PubMed

Nat Rev Immunol. 2004 Jul;4(7):499-511 PubMed

Neurosci Lett. 2008 May 9;436(2):259-64 PubMed

J Biol Chem. 1999 Apr 16;274(16):10689-92 PubMed

J Neurosci. 2017 Apr 19;37(16):4255-4269 PubMed

Blood. 2008 Apr 1;111(7):3701-13 PubMed

J Neurochem. 1996 Jul;67(1):1-10 PubMed

Curr Opin Genet Dev. 2010 Feb;20(1):65-71 PubMed

Glia. 2006 Jan 1;53(1):103-13 PubMed

Mol Cell Neurosci. 2013 Sep;56:272-82 PubMed

J Neuroimmunol. 2009 Jul 25;212(1-2):26-34 PubMed